Bladder Cancer

touchONCOLOGY joins Professor Stephen B Williams (Chief, Division of Urology, Professor of Urology and Radiology, Division of Urology, The University of Texas Medical Branch, Galveston, TX, USA) at ASCO 2021 to discuss the efficacy of TAR-200 in combination with cetrelimab in participants with muscle-invasive urothelial carcinoma of the bladder. The abstract ‘A phase 3, multicenter, […]

touchONCOLOGY joins Dr Joaquim Bellmunt (Director, Bladder Cancer Program, Beth Israel Deaconess Medical Center; Associate Professor of Medicine, Harvard Medical School, Boston, MA, USA) at ASCO 2021 to discuss the 5-year follow-up from the phase 3 KEYNOTE-045 trial. The abstract ‘A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial […]

touchONCOLOGY joins Dr Alison Birtle (Consultant Oncologist and Honorary Senior Lecturer, Rosemere Cancer Centre, Lancashire Teaching Hospitals, Preston, UK) to discuss the updated primary and secondary analysis of the POUT trial in upper tract urothelial cancer (ClinicalTrials.gov Identifier: NCT01993979). The abstract “Updated outcomes of POUT: A phase III randomized trial of peri-operative chemotherapy versus surveillance […]

Urothelial carcinoma is the most common histologic type of bladder cancer in the USA and Europe, accounting for 90% of all bladder cancers. It is the sixth most common type of cancer diagnosed in the USA, and the 10th leading cause of cancer death, with an estimated 17,980 deaths predicted in 2020.1 Although the 5-year survival […]

It was a pleasure to speak to Thomas Powles about his plenery session on the phase III interim analysis of the JAVELIN Bladder 100 study on maintenance avelumab and best supportive care (BSC) versus BSC alone after platinum-based first-line chemotherapy in advanced urothelial carcinoma. Questions 1. What have we learned so far from clinical trials […]

We joined Petros Grivas (University of Washington School of Medicine) at ESMO 2019 to discuss immune checkpoint inhibitors and novel agents in the treatment of metastatic urothelial cancer. Questions 1. How have immune checkpoint inhibitors changed the treatment landscape for metastatic urothelial cancer? (0:04) 2. What progress has been made in identifying biomarkers of response […]

We are joined by Arlene Sietker-Radtke (The University of Texas MD Anderson Cancer Center) at ESMO 2019 to discuss her presentation on the results from the KEYNOTE-866 trial (NCT03924856). This phase III study investigates perioperative pembrolizumab or placebo in combination with neoadjuvant chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer. Questions What are the limitations […]

Enrique Grande (MD Anderson Cancer Center) discusses evolving immunotherapy combination strategies in the first line treatment of urothelial cancer at ESMO 2019. Questions 1. In which patients with urothelial cancer is immunotherapy indicated as first-line therapy? (0:04) 2. How can we improve response rates to immune checkpoint inhibitors in patients with urothelial cancer? (0:09) 3. […]

With an estimated 549,000 new diagnoses and 200,000 deaths worldwide in 2018, bladder cancer is the tenth most common type of cancer in men and women.¹ The most common type of bladder cancer in the Western world is uroepithelial carcinoma, which accounts for 90% of all cases, and is classified into two subtypes. Non-muscle-invasive urothelial carcinomas (NMIBC) are associated with activation of the receptor tyrosine kinase-Ras pathway, activating mutations […]